Evidence map›Paper›PMID 25481829›Full record

Trial reportJournal of the National Cancer Institute2014

Increasing colon cancer screening in primary care among African Americans.

Ronald E Myers, Randa Sifri, Constantine Daskalakis, Melissa DiCarlo, Praveen Ramakrishnan Geethakumari, James Cocroft, Christopher Minnick, Nancy Brisbon, Sally W Vernon

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 6 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 6 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Precision Patient Navigation to Improve Rates of Follow-up Colonoscopy, An Individual Randomized Effectiveness Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Trial
  10. Trial
  11. An RCT to Increase Breast and Colorectal Cancer Screening.American journal of preventive medicine · 2020
    Trial
  12. Trial
  13. Trial
  14. Impact of Risk Assessment and Tailored versus Nontailored Risk Information on Colorectal Cancer Testing in Primary Care: A Randomized Controlled Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ronald E Myers: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV). ronald.myers@jefferson.edu.
Randa Sifri: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Constantine Daskalakis: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Melissa DiCarlo: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Praveen Ramakrishnan Geethakumari: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
James Cocroft: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Christopher Minnick: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Nancy Brisbon: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Sally W Vernon: Division of Population Science, Medical Oncology (REM, MD, JC), Department of Family and Community Medicine (RS, NB), and Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics (CD), Thomas Jefferson University, Philadelphia, PA; Department of Internal Medicine, Albert Einstein Healthcare Network (PRG); Cancer Center, Albert Einstein Healthcare Network, Philadelphia, PA (CM); Division of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention Research, University of Texas School of Public Health, Houston, TX (SWV).
Einstein Healthcare Network · USThomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
NCI NIH HHS P30 CA056036
6 · The paper itself

Abstract

backgroundThe study aimed to determine the effect of preference-based tailored navigation on colorectal cancer (CRC) screening adherence and related outcomes among African Americans (AAs).

methodsWe conducted a randomized controlled trial that included 764 AA patients who were age 50 to 75 years, were eligible for CRC screening, and had received care through primary care practices in Philadelphia. Consented patients completed a baseline telephone survey and were randomized to either a Standard Intervention (SI) group (n = 380) or a Tailored Navigation Intervention (TNI) group (n = 384). The SI group received a mailed stool blood test kit plus colonoscopy instructions, and a reminder. The TNI group received tailored navigation (a mailed stool blood test kit or colonoscopy instructions based on preference, plus telephone navigation) and a reminder. A six-month survey and a 12-month medical records review were completed to assess screening adherence, change in overall screening preference, and perceptions about screening. Multivariable analyses were performed to assess intervention impact on outcomes.

resultsAt six months, adherence in the TNI group was statistically significantly higher than in the SI group (OR = 2.1, 95% CI = 1.5 to 2.9). Positive change in overall screening preference was also statistically significantly greater in the TNI group compared with the SI group (OR = 1.5, 95% CI = 1.0 to 2.3). There were no statistically significant differences in perceptions about screening between the study groups.

conclusionsTailored navigation in primary care is a promising approach for increasing CRC screening among AAs. Research is needed to determine how to maximize intervention effects and to test intervention impact on race-related disparities in mortality and survival.

Indexed as

Patient NavigationReminder SystemsAgedBlack or African AmericanColonic NeoplasmsColonoscopyEarly Detection of CancerFemaleHumansMaleMass ScreeningMiddle AgedOccult BloodPatient CompliancePhiladelphiaPrimary Health Care

Identifiers

PMID25481829
PMCPMC4817126
OpenAlexW2137718259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.